Jorge Cortes-Franco, MD
Hematology & Oncology · Houston, TXNPI 1578658480
Payments from drug & device makers
Across 423 payments — averaging $140,414 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$36.1M
- E.r. Squibb & Sons, L.L.C.$13.9M
- Astellas Pharma Inc$6.5M
- Pfizer$1.4M
- Jazz Pharmaceuticals Inc.$757K
- Takeda Pharmaceuticals U.S.A., Inc.$132K
- plus $576K from 26 others
Across 129 payments — averaging $1210.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$85K
- Novartis$33K
- Novartis Pharma AG$30K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Astellas Pharma Global Development$3K
- Amgen$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 84 | $36,087,736 |
| E.r. Squibb & Sons, L.L.C. | 12 | $13,946,449 |
| Astellas Pharma Inc | 1 | $6,500,000 |
| Pfizer(2 entities) | 106 | $1,396,501 |
| Jazz Pharmaceuticals Inc. | 7 | $756,873 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $131,553 |
| Daiichi Sankyo Inc. | 35 | $126,987 |
| AbbVie | 20 | $123,286 |
| Otsuka Pharmaceutical Co., Ltd. | 29 | $93,602 |
| Astellas Pharma Global Development | 8 | $59,318 |
| Novartis Pharma AG | 19 | $37,963 |
| Incyte Corporation | 1 | $30,016 |
| Gilead(2 entities) | 6 | $19,528 |
| Daiichi Sankyo Europe GmbH | 2 | $16,720 |
| Laboratorios Pfizer Lda. | 4 | $13,620 |
| Rigel Pharmaceuticals, Inc. | 10 | $11,218 |
| Bristol Myers Squibb | 4 | $9,690 |
| Astellas Pharma US Inc | 5 | $6,393 |
| Glenmark Pharmaceuticals Limited | 1 | $4,500 |
| Daiichi Sankyo Company LTD | 2 | $4,145 |
| Agios Pharmaceuticals, Inc. | 1 | $3,300 |
| Beigene, Ltd. | 1 | $2,600 |
| Syndax Pharmaceuticals, Inc. | 1 | $2,400 |
| Sun Pharmaceutical Industries Inc. | 1 | $2,399 |
| Whitehall International Inc | 1 | $2,250 |
| Pfizer Chile S.A. | 4 | $2,222 |
| Cycle Pharmaceuticals Inc | 1 | $1,900 |
| PTC Therapeutics, Inc. | 2 | $1,317 |
| Amgen | 3 | $256 |
| AstraZeneca | 1 | $135 |
| Johnson & Johnson | 2 | $86 |
| Beigene USA, Inc. | 1 | $13 |
How this compares
$59,394,974 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Philip ThompsonHouston$13.6M
- Naval DaverHouston$13.6M
- Ghayas IssaHouston$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.